--12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 14, 2024
TG Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware | 001-32639 | 36-3898269 |
| (State or Other Jurisdiction | (Commission File Number) | (IRS Employer Identification No.) |
| of Incorporation) | | |
3020 Carrington Mill Blvd, Suite 475
Morrisville, North Carolina 27560
(Address of Principal Executive Offices)
(212) 554-4484
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities filed pursuant to Section 12(b) of the Act:
Title of Class | Trading Symbol(s) | Exchange Name |
| Common Stock | TGTX | Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
As described under Item 5.07 of this Current Report, on June 14, 2024, the stockholders of TG Therapeutics, Inc., (the “Company”) voted at the Company’s 2024 annual meeting of stockholders (the “2024 Annual Meeting”) to approve an amendment to the Company’s 2022 Incentive Plan to remove the full-value awards limit.
A copy of the amendment to the Company’s 2022 Incentive Plan is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 5.02. A copy of the amendment to the Company’s 2022 Incentive Plan was filed as Appendix B to the proxy statement on Schedule 14A for the 2024 Annual Meeting filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2024.
Item 5.03. | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year |
As described under Item 5.07 of this Current Report, on June 14, 2024, the stockholders of the Company voted at the 2024 Annual Meeting to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 175,000,000 to 190,000,000 (the “Amendment”).
On June 14, 2024, following the 2024 Annual Meeting, the Company filed a certificate of amendment (the “Certificate”) giving effect to the Amendment with the Secretary of State of the State of Delaware. A copy of the Certificate is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 5.03. A copy of the Amendment was filed as Appendix A to the proxy statement on Schedule 14A for the 2024 Annual Meeting filed with the SEC on April 29, 2024.
Item 5.07. | Submission of Matters to a Vote of Security Holders. |
On Thursday, June 14, 2024, at 9:30 a.m. Eastern Time, by means of an online meeting platform, the Company held its 2024 Annual Meeting. Stockholders representing 111,075,029, or 71.87%, of the 154,542,945 outstanding shares were present in person or by proxy, constituting a quorum under applicable law. Proxies were solicited by the Company pursuant to Regulation 14A under the SEC. Each of the proposals below are described in detail in the Company’s definitive proxy statement on Schedule 14A for the 2024 Annual Meeting, filed with the SEC on April 29, 2024. At the 2024 Annual Meeting, all of the proposals were approved.
The results are as follows:
Proposal 1
The votes with respect to the election of the six directors to hold office until the 2025 annual meeting were as follows:
Director | Votes For | % Voted For | Votes Withheld | % Voted Withheld | Broker Non- Votes |
Michael S. Weiss | 57,264,472 | 75.23% | 18,849,954 | 24.77% | 34,960,603 |
Laurence N. Charney | 57,758,626 | 75.88% | 18,355,800 | 24.12% | 34,960,603 |
Yann Echelard | 35,052,596 | 46.05% | 41,061,830 | 53.95% | 34,960,603 |
Kenneth Hoberman | 52,058,723 | 68.40% | 24,055,703 | 31.60% | 34,960,603 |
Daniel Hume | 35,036,823 | 46.03% | 41,077,603 | 53.97% | 34,960,603 |
Sagar Lonial, MD | 33,299,870 | 43.75% | 42,814,556 | 56.25% | 34,960,603 |
Proposal 2
The vote with respect to the ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was as follows:
Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
| 110,028,319 | 657,578 | 389,132 | -- |
Proposal 3
The advisory vote to approve the compensation of the Company’s named executive officers was as follows:
Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
| 42,346,581 | 31,019,084 | 2,748,761 | 34,960,603 |
Proposal 4
The vote to approve the amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 175,000,000 to 190,000,000 was as follows:
Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
| 73,780,225 | 36,348,764 | 946,040 | -- |
Proposal 5
The vote to approve the amendment to the Company’s 2022 Incentive Plan to remove the full-value awards limit was as follows:
Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
| 66,744,142 | 8,625,685 | 744,599 | 34,960,603 |
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit
No. | | Description |
| 3.1 | | |
| | | |
| 10.1 | | |
| | | |
| 104 | | Cover Page Interactive Data File (embedded within Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TG THERAPEUTICS, INC. | |
| | (Registrant) | |
| | | |
| | | | |
| | | | |
| | | |
| Date: June 17, 2024 | By: | /s/ Sean A. Power | |
| Name: | Sean A. Power | |
| Title: | Chief Financial Officer | |
